Malignancy as a Solid-Phase Coagulopathy: Implications for the Etiology, Pathogenesis, and Treatment of Cancer

ABSTRACT

This overview of the coagulation biology of cancer is intended primarily for those unfamiliar with the link between the coagulation mechanism and neoplasia. Because the literature on this topic is extensive, citations will be primarily of previous reviews that provide detailed references. The clotting mechanism is fundamentally deranged in malignancy and, unlike the physiological hemostatic response to injury, is incapable of self-attenuation. Clotting activation may predict future cancer and the outcome of existing cancer, and participates in tumor growth. Anticoagulant therapy in patients with malignancy achieves more than control of cancer-related thrombosis. Modification of coagulation reactions relevant to particular tumor types improves the course of the disease. Viewing malignancy as a solid-phase coagulopathy provides insights into possible "upstream" causes of malignant transformation and explanations for the aberrant behavior of transformed cells and suggests innovative experimental interventions. Coagulation biology has broadened and deepened our understanding of neoplasia, and suggested testable strategies for the prevention and treatment of cancer. However, relationships between clotting and cancer progression have been established primarily from model systems. Although limited experience to date in human disease has supported these concepts, resolution of cause-and-effect relationships will require performance of additional rationally designed clinical trials.

KEYWORDS

Blood coagulation - anticoagulants - malignancy - cancer treatment

REFERENCES

• 1 Rickles F R, Levine M N, Dvorak H F. Abnormalities of hemostasis in malignancy. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2001 : 1131-1152
• 2 Burnes J. Dissertations on Inflammation, Vol I.  Albany, NY: EF Backus 1812
• 3 DeVita V A, Hellman S, Rosenberg R A. Cancer: Principles & Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2001
• 4 Zacharski L R, Wojtukiewicz M Z, Costantini V, Ornstein D L, Memoli V A. Pathways of coagulation/fibrinolysis activation in malignancy.  Semin Thromb Hemost . 1992;  18 104-116
• 5 Meehan K R, Zacharski L R, Moritz T E, Rickles F R. Pretreatment fibrinogen levels predict response to chemotherapy in small cell carcinoma of the lung.  Am J Hematol . 1995;  49 143-148
• 6 Milroy R, Douglas J T, Campbell J. et al . Abnormal haemostasis in small cell lung cancer.  Thorax . 1988;  43 978-981
• 7 Costantini V, Zacharski L R, Memoli V A. et al . Fibrinogen deposition and macrophage-associated fibrin formation in malignant and non-malignant lymphoid tissue.  J Lab Clin Med . 1992;  119 124-131
• 8 Thodiyil P A, Kakkar A K. Variation in relative risk of venous thromboembolism in various cancers.  Thromb Haemost . 2002;  87 1076-1077
• 9 Costantini V, Zacharski L R, Memoli V A. et al . Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.  Cancer Res . 1991;  51 349-353
• 10 Costantini V, Zacharski L R, Memoli V A. et al . Occurrence of components of fibrinolysis pathways in situ in neoplastic and non-neoplastic human breast tissue.  Cancer Res . 1991;  51 354-358
• 11 Korte W. Changes in the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.  Clin Chem Lab Med . 2000;  38 679-692
• 12 Edwards R L, Rickles F R, Moritz T E. et al . Abnormalities of blood coagulation tests in patients with cancer.  Am J Clin Pathol . 1987;  88 596-602
• 13 Deitscher S R. Cancer-related deep venous thrombosis: clinical importance, treatment challenges and management strategies.  Semin Thromb Hemost . 2003;  29 247-258
• 14 Francis J L, Amirkhosravi A. Effect of antimetastatic agents on experimental tumor dissemination.  Semin Thromb Hemost . 2002;  28 29-38
• 15 Dembski W A, Kushiner J M. Signs of Intelligence . Grand Rapids, MI: Brazos Press 2001
• 16 Pihusch R, Danzl G, Scholz M. et al . Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma.  Cancer. 200;  200 3120-3126
• 17 Liu D, Shriver Z, Venkataraman G, Shabrawi Y, Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters of inhibitors of tumor growth and metastasis.  Proc Natl Acad Sci USA . 2002;  99 568-573
• 18 Richmond R A, Thomas H G. Melanoma growth stimulating activity: isolation from human melanoma tumors and characterization of tissue distribution.  J Cell Biochem . 1988;  36 185-198
• 19 Zugmaier G, Favoni R, Jaeger R, Rosen N, Knabbe C. Polysulfated heparinoids selectively inactivate heparin-binding angiogenic factors.  Ann NY Acad Sci . 1999;  886 243-248
• 20 Zacharski L R, Loynes J R, Ornstein D L, Rigas J R. The plasminogen system and cancer.  Biomed Prog . 2002;  15 17-22
• 21 Zacharski L R, Ornstein D L. Heparin and cancer.  Thromb Haemost . 1998;  80 10-23
• 22 Lentschener C, Li C H, Franco D. et al . Intraoperatively-administered aprotinin and survival after elective liver resection for colorectal cancer metastasis. A preliminary study.  Fibrinolysis Proteolysis . 1999;  13 39-45
• 23 Zacharski L R, Morain W D, Schlaeppi J-M, Memoli V A, Rousseau S M. Cellular localization of enzymatically active thrombin in intact human tissue by hirudin binding.  Thromb Haemost . 1995;  73 793-797
• 24 Coughlin S R. Thrombin signaling and protease-activated receptors.  Nature . 2000;  407 258-264
• 25 Mousa S A. Anticoagulants in thrombosis and cancer: the missing link.  Semin Thromb Hemost . 2002;  28 45-52
• 26 Trikha M, Nakada M T. Platelets and cancer: implications for antiangiogenic therapy.  Semin Thromb Hemost . 2002;  28 39-44
• 27 Dunbar S D, Ornstein D L, Zacharski L R. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.  Exp Opin Invest Drugs . 2000;  9 2085-2092
• 28 Wojtukiewicz M Z, Rucinska M, Zacharski L R. et al . Blood coagulation activation in situ in pancreatic cancer tissue.  Thromb Haemost . 2001;  86 1416-1420
• 29 Zacharski L R, Ornstein D L, Gabazza E C. et al . Treatment of malignancy by activation of the plasminogen system.  Semin Thromb Hemost . 2002;  28 5-17
• 30 Zacharski L R, Donati M B, Rickles F R. Registry of clinical trials of antithrombotic drugs in cancer: second report.  Thromb Haemost . 1993;  70 357-360
• 31 Ornstein D L, Zacharski L R. Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.  Int J Hematol . 2001;  73 157-161
• 32 Zacharski L R, Henderson W G, Rickles F R. et al . Effect of sodium warfarin on survival in small cell carcinoma of the lung.  JAMA . 1981;  245 831-835
• 33 Chahinian A P, Propert K J, Ware J H. et al . A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.  J Clin Oncol . 1989;  7 993-1002
• 34 Maurer L H, Herndon II E J, Hollis D R. et al . Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited stage small cell lung cancer: CALGB protocol 8534.  J Clin Oncol . 1997;  15 3378-3387
• 35 Lebeau B, Chastang C, Brechot J-M. et al . Subcutaneous heparin treatment increases survival in small cell lung cancer.  Cancer . 1994;  74 38-45
• 36 Calvo F A, Hidalgo O F, Gonzales F. et al . Urokinase combination chemotherapy in small cell lung cancer. A phase II study.  Cancer . 1992;  70 2624-2630
• 37 Zacharski L R, Henderson W G, Rickles F R. et al . Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate: final report of VA Cooperative Study #75.  Cancer . 1984;  53 2046-2052
• 38 Prandoni P, Lensing A W, Cogo S. et al . The long-term course of acute deep vein thrombosis.  Ann Intern Med . 1996;  125 1-7
• 39 Lyberg T, Prydz H. Phorbol esters induce synthesis of thromboplastin activity in human monocytes.  Biochem J . 1981;  194 699-706
• 40 Pangasnan R S, Deversux D, DeCunzo L P, Karp G I. The production of a factor X activator by a methylcholanthrene-induced rat fibrosarcoma.  Thromb Haemost . 1992;  68 407-412
• 41 Zacharski L R, Costantini V, Moritz T E, Haakenson C M. Chronic nonsteroidal anti-inflammatory drug use in a cohort of patients with advanced lung and colon cancer. In: Honn KV, Nigam S, Walden T, eds. Prostaglandins, Leukotrienes and Cancer Dordrecht, The Netherlands: Kluwer 1991: 497-501
• 42 Hawk E T, Viner J L, Dunnenberg A, DuBois R N. COX-2 in cancer-a player that's defining the rules.  J Natl Cancer Inst . 2002;  94 545-546
• 43 Blanke C D. Celecoxib with chemotherapy in colorectal cancer.  Oncology . 2002;  16(Suppl) 17-21
• 44 Schulman S, Lindmaker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism.  N Engl J Med . 2000;  342 1953-1958
• 45 Zacharski L R, Ornstein D L. Venous thromboembolism and cancer.  N Engl J Med . 2000;  343 1337-1338
• 46 Sciumbata T, Pirovano P, Pozzi P. et al . Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival.  Invasion Metastasis . 1996;  16 132-143
• 47 von Tempelhoff G-F, Harenberg J, Niemann F. et al . Effect of low molecular weight heparin (Cetoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial.  Int J Oncol . 2000;  16 815-824
• 48 Zacharski L R, Henderson W B. Vitamin K antagonists and cancer survival.  Thromb Haemost . 2002;  88 173-174
• 49 Dvorak H F. Tumors: wounds that do not heal.  N Engl J Med . 1986;  315 1650-1659
• 50 Gordon B L. Is intelligent design science? The scientific status and future of design theory explanation. In: Dembski WA, Kushiner JM, eds. Signs of Intelligence. Grand Rapids, MI: Brazos Press 2001